Presented by
SOSS Event Coverage
Emerging Maintenance Strategies May be the Key to Extending Survival in ES-SCLC
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention
Judy Wang, MD, discusses how ADCs are transforming NSCLC treatment with improved responses, biomarker-driven care, and CNS activity.
Axi-Cel Advances Signal Shifts Toward Earlier-Line Applications in LBCL
Taylor Brooks, MD, discusses the effects of CAR T-cell therapy on LBCL management and the efficacy of axi-cel for patients with relapsed/refractory LBCL.
JAK Inhibitors Persist, While Novel Agents Aim for Disease Modification in Myelofibrosis
Aaron Gerds, MD, MS, discusses the clinical applications of each of the FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.
Evolving Options for SCLC Management Drive the Need for Increasingly Personalized Approaches
Misty D. Shields, MD, PhD, discusses the importance of approving novel treatments for SCLC and developmental drugs that may challenge the current paradigm.
Chemoradiotherapy Data, PCI Controversy, and Translational Research Advance SCLC Care
Misty D. Shields, MD, PhD, discusses the inefficacy of concurrent immunotherapy and chemoradiation in lung cancer and the debate surrounding PCI in SCLC.
Evolving Treatment Strategies Reshape the Landscape of Hematologic Malignancies
Naseema Gangat, MBBS, details updates, novel strategies, and factors that inform decision-making in clinical for patients with hematologic malignancies.
PARP Inhibitors and Radioligand Therapies Advance Prostate Cancer Care with Biomarker-Driven Strategies
Matthew R. Smith, MD, PhD, discusses how PARP inhibition and radioligand therapies are shaping treatment decisions in advanced prostate cancer.
Considerations for Selection and Sequencing in Polycythemia Vera and Myelofibrosis
Naseema Gangat, MBBS, delves into the role of ruxolitinib as a standard of care for the treatment of patients with polycythemia vera and myelofibrosis.
Darolutamide Doublet Is Redefining Treatment Decision-Making for mCSPC
Matthew R. Smith, MD, PhD, discusses findings from the ARANOTE trial that confirm the efficacy of darolutamide plus ADT in mCSPC.
Immunotherapy and T-Cell–Directed Therapy Expand Treatment Approaches in Small Cell Lung Cancer
Sonam Puri, MD, discusses advances in small cell lung cancer that have expanded treatment options across disease stages.
Expansion of BTK and BCL2 Inhibitors in CLL Requires Close Attention to Safety, Sequencing Considerations
Andrew Kuykendall, MD, discusses the evolving role of BTK inhibitors, as well as emerging targets and treatment modalities targeting BTK and BCL2 in CLL.
Consensus on Clinical Trial End Points Is Essential for Improved Drug Development Across MPNs
Andrew Kuykendall, MD, outlines the limitations of current clinical end points and discusses the need for molecularly informed drug development in MPN.
From BTK Inhibitors to CAR T-Cell Therapies: Hematologic Malignancies Landscape Sees an ‘Explosion of New Therapies’
Kathleen A. Dorritie, MD, highlights important NCCN guideline updates and research to watch in hematologic malignancies.
Shift Toward Chemotherapy-Free Approaches Redefines Upfront CLL Treatment Selection
Kathleen A. Dorritie, MD, discusses 2 clinical scenario cases to showcase differences in the management of newly diagnosed vs relapsed/refractory CLL.
Lineage Plasticity and Treatment Resistance Highlight Need for Personalized mCRPC Strategies
Jue Wang, MD, outlines how prolonged androgen suppression may drive prostate cancer evolution.
Real-World Treatment Gaps in mCRPC Reinforce the Need for Personalized Selection and Sequencing
Jue Wang, MD, discusses persistent gaps between clinical advances and real-world care and the evolving role of personalized treatment strategies in mCRPC.
Long-Term Follow-Up Data With IO/IO and IO/TKI Combinations Better Inform Clinical Decision-Making in Advanced ccRCC
Hans Hammers, MD, PhD, discusses the efficacy, safety, and clinical utilization of IO/IO and IO/TKI combinations in advanced clear-cell RCC.
Contrasting Adjuvant and Perioperative Trial Designs Help Refine MIBC Management
Petros Grivas, MD, PhD, discusses data from CheckMate 274 and how emerging data from bladder cancer trials are shaping immunotherapy strategies in MIBC.
NIAGARA Trial Validates Perioperative Durvalumab Approach in MIBC
Petros Grivas, MD, PhD, discusses key findings from the NIAGARA trial and how these data support the use of perioperative durvalumab in MIBC management.
Targeted Therapy Developments and Screening Updates Broaden the NSCLC Treatment Paradigm
Alexis Chidi, MD, PhD, MSPH, emphasizes the importance of having more available targeted therapies and explains NSCLC screening eligibility criteria.
PSMA PET Guides the Individualized Use of Lutetium-Based Therapies in mCRPC
Evan Y. Yu, MD, discusses the clinical evolution of radiopharmaceuticals for patients with mCRPC and how PSMA PET may evolve to monitor treatment response.
Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment
Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.
Personalized Therapy, Surgical Staging, and Expanded Screening Guidelines Drive Progress in NSCLC
Isabel Preeshagul, DO, MBS, discusses the need for a nuanced approach when selecting between targeted therapies in ALK- and EGFR-altered NSCLC.
Tarlatamab and Durvalumab Enhance the SCLC Immunotherapy Paradigm
Isabel Preeshagul, DO, MBS, discusses frontline treatment selection for patients with SCLC and significant FDA approvals in this disease.
Talazoparib/Enzalutamide Combo, Radioligand Therapy Expand Options in mCRPC
Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for advanced metastatic prostate cancer.
Anthracycline-Sparing Strategies Help Refine HER2+ Breast Cancer Management
Paolo Tarantino, MD, discusses the growing emphasis on anthracycline-sparing approaches for the treatment of HER2-positive breast cancer.
Targeted Therapies Both Refine and Raise Questions About CRPC Treatment Decision-Making
Evan Y. Yu, MD, discusses PARP inhibitor treatment selection and sequencing for patients with metastatic castration-resistant prostate cancer.
RCC Treatment Decision-Making Requires a Balance of Efficacy and Individual Patient Considerations
Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for renal cell carcinoma.
Newly Approved ADCs Expand Options in HR+ Metastatic Breast Cancer
Sara Nunnery, MD, MSCI, discusses the impact of the approvals of T-DXd and Dato-DXd in HR-positive breast cancer and sequencing questions with ADCs.
